Sign in Membership

Strategic Intelligence on China’s Health Policy, Coverage, and Financing System

Helping life sciences leaders navigate China’s health policy, coverage, and financing complexity for medical technologies — and translate system change into clearer access strategy and better-informed commercial decisions.

Published in Caixin and China Reform Magazine

Share the China access topics you would like covered in the Mid-Year Strategic Debrief and receive a complimentary executive summary in August.

Share Your Perspective

Engagement Paths

Access360

Access360 combines timely interpretation, synthesized strategic outlooks, and member Q&A to help life sciences leaders navigate China access decisions and pressure-test market assumptions across health policy, coverage, financing, and implementation uncertainty.

→ Explore Access360 Membership

China Access Outlook: Strategic Debrief

A mid-year and annual executive synthesis of major developments shaping China’s health policy, pricing, coverage, financing, and adoption environment for medical technologies — helping senior leaders understand what changed, why it matters, and what to watch next.

Available as on-demand executive briefings for standalone purchase or included with Access360 membership.

→ Share Your Perspective — Receive the Complimentary Executive Summary

NRDL+ Masterclass

Executive strategic foundation for China access decision-making.

Through structured interpretation and guided case application, participants connect system-level signals to strategic trade-offs and execution constraints in China’s evolving coverage landscape.

→ Explore NRDL+ Masterclass

Latest Access360 Briefings

Jun 17, 2026

China’s C-List and Beyond: Group Insurance, Provider Uptake, and Commercial Payment Strategies

A practical implementation deep-dive with Professor Wanyan on China’s C-List and broader commercial payment landscape — covering group health insurance, provider uptake, cross-stakeholder bottlenecks, orphan therapy coverage, TPAs, and scalable payment strategy.
Jun 10, 2026

China’s C-List in Practice: Early Huiminbao Integration Signals

A practical discussion with Professor Wanyan on Huiminbao benefit design changes, regional adoption differences, local negotiation dynamics, and what early implementation may signal for broader commercial insurance integration.
Jun 03, 2026

China’s C-List: Behind-the-Scenes Negotiation Dynamics

A practical implementation deep-dive into China’s 2025 C-List negotiation process with Professor Wanyan — covering insurer participation, NHSA’s role, selection criteria, pricing negotiation, and future commercial insurance formulary trends.
May 15, 2026

China’s 2026 Dual-List Draft Workplan: Earlier Innovation Access, Tighter Lifecycle Pricing Discipline

China’s 2026 NRDL draft workplan signals a more integrated, lifecycle-oriented reimbursement framework: earlier access for innovative therapies, closer regulatory–reimbursement alignment anchored in RWE, and tighter pricing discipline for mature and me-too products.
Apr 09, 2026

China’s Healthcare System Is Reorganizing: What It Means for Manufacturers

As China’s healthcare system reorganizes, evolving care pathways and payment dynamics are reshaping how access is secured and how value is realized.
Mar 12, 2026

RWE and the Quiet Rewiring of China’s Reimbursement System

Five recent policy releases show how real-world evidence is quietly reshaping pricing, reimbursement, and clinical adoption for both innovative and established medicines in China.